CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma
CHUAN JIANG1,2, CHUNLEI LIU1,3, XI YAO1,3, JINGYA SU1,2, WEI LU1,3, ZHENGBO WEI3,*, YING XIE1,2,*
Oncology Research, Vol.32, No.12, pp. 1935-1948, 2024, DOI:10.32604/or.2024.052244
- 13 November 2024
Abstract Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent form of cancer globally, with chemoresistance posing a major challenge in treatment outcomes. The efficacy of the commonly used chemotherapeutic agent, cisplatin, is diminished in patients with poor prognoses. Methods: Various bioinformatics databases were utilized to examine Carboxylesterase 1 (CES1) gene expression, clinicopathologic features, patient survival analysis, and gene function. An organoid model of HNSCC was established, along with the induction of drug-resistant HNSCC in the organoid model. CES1 expression was assessed using qRT-PCR and Western Blot, and differential markers were identified through transcriptome… More >